| 摘要: |
| 目的:基于Meta分析系统评价宁泌泰联合左氧氟沙星治疗慢性前列腺炎的疗效及安全性。方法:计算机检索中国知网、万方、维普、PubMed、Medline、Corchrane Library及Embase数据库，收集有关宁泌泰联合左氧氟沙星治疗慢性前列腺炎的临床随机对照试验(RCT)研究文献。文献检索年限为建库初始至2020年9月，依据疾病的纳入和排除标准提取数据，采用RevMan5.3软件进行Meta分析。结果:共纳入18项RCT，涉及2 504例患者。Meta分析结果显示:与对照组相比，宁泌泰联合左氧氟沙星治疗慢性前列腺炎能显著提高患者的临床疗效[OR=2.92, 95%CI(2.35,3.63), P<0.001]，降低前列腺炎症状指数(NIH-CPSI评分)[MD=-5.13,95%CI(-8.72,-1.54), P<0.001]、白细胞介素-2(IL-2)水平[SMD= -0.79,95%CI(-0.97,-0.60), P<0.001]、白细胞介素-6(IL-6)水平[SMD=-0.85,95%CI(-1.04,-0.66), P<0.001]，两组不良反应发生率比较差异无统计学意义[RR=1.00,95%CI(0.58,1.72), P=1.00]。结论:宁泌泰联合左氧氟沙星治疗慢性前列腺炎能明显提高临床疗效，降低NIH-CPSI评分，消除炎症细胞，减少不良反应。 |
| 关键词: 慢性前列腺炎 宁泌泰 左氧氟沙星 Meta分析 |
| DOI：10.3969/j.issn.1007-6948.2021.03.013 |
| 投稿时间：2020-10-01 |
| 基金项目:北京中医药大学新教师启动基金项目(2018-JYB22XJSJJ035) |
|
| Meta Analysis of Ningmitai Combined with Levofloxacin in Treatment of Chronic Prostatitis |
| ZHANG Chen,XI Jin-bo,LUO Rui-xiang |
|
| Abstract: |
| Objective To evaluate the efficacy and safety of Ningmitai combined with levofloxacin in the treatment of chronic prostatitis based on meta-analysis. Methods Computer data retrieved from CNKI,WanFang,VIP,PubMed, Medline,Corchrane Library and Embase databases wascollectedbythe randomized controlled trials (RCTs) for chronic prostattis with Ningmitai combined with levofloxacin.The literature retrieval period was from the initial construction of the database to September 2020. Data was extracted according to the inclusion and exclusion criteria of diseases, and Meta analysis was carried out by using RevMan 5.3 software. Results A total of 18 RCTs were included,involving 2504 patients.Meta analysis results showed that compared with the control group,Ningmitai combined with levofloxacin could significantly improve the clinical efficacy of patients with chronic prostatitis:[OR=2.92, 95%CI(2.35,3.63), P<0.001], reduce NIH-CPSI score:[MD=-5.13, 95%CI(-8.72,-1.54), P<0.001], reduce the count of interleukin-2(IL-2): [SMD=-0.79, 95%CI(-0.97,-0.60), P<0.001], reduce the count of interleukin-6(IL-6): [SMD=-0.85, 95%CI(-1.04,-0.66), P<0.001] and reduce the incidence of adverse reactions:[RR=1.00,95%CI(0.58,1.72), P=1.00]. Conclusion Ningmitai combined with levofloxacin in the treatment of chronic prostatitis can significantly improve the clinical efficacy,reduce the NIF-CPSI score,eliminate inflammatory cells and reduce adverse reactions. |
| Key words: Chronic prostatitis Ningmitai levofloxacin meta analysis |
